Ipsen
Ipsen works on 17 rare diseases tracked on Trial Friend, including Acromegaly, Alagille Syndrome, Duchenne Muscular Dystrophy and 14 more, with 19 recruiting clinical trials and 5 FDA-approved rare disease drugs.
Ipsen is a French biopharmaceutical company focused on oncology, rare diseases, and neuroscience. Key rare disease products include Somatuline Depot (lanreotide) for acromegaly, Sohonos (palovarotene) for fibrodysplasia ossificans progressiva, Bylvay (odevixibat) for progressive familial intrahepatic cholestasis and Alagille syndrome pruritus, and Iqirvo (elafibranor) for primary biliary cholangitis (approved 2024). The company also has elafibranor in Phase 2 for primary sclerosing cholangitis.
Focus areas at Ipsen
Within its broader pharmaceutical portfolio, Ipsen has active clinical trial programs and drug development efforts across 17 rare diseases, including Acromegaly, Alagille Syndrome, Duchenne Muscular Dystrophy, Fibrodysplasia Ossificans Progressiva, Friedreich Ataxia, and 12 additional rare conditions. These programs may span orphan drug designation, novel therapeutic mechanisms, and precision medicine approaches targeting the underlying causes of each disease.
The clinical trials section below shows all active and recruiting studies sponsored by Ipsen, sourced live from ClinicalTrials.gov. Each trial includes its current recruitment status, study phase (Phase 1 through Phase 4), conditions under investigation, and the number of active trial sites. The FDA-approved drugs section lists treatments that have received U.S. Food and Drug Administration approval, with brand names, generic names, approval dates, and matched rare disease indications from the openFDA database.
Ipsen is headquartered in Paris, France, founded in 1929, publicly traded under the ticker symbol IPSEY. The company maintains a dedicated rare disease division alongside its broader therapeutic portfolio, working to bring innovative treatments to patients with conditions that have historically had limited or no treatment options.
Ipsen Drug Pipeline
Ipsen has 19 active clinical trials across 5 development stages, with 19 currently recruiting participants. Clinical trials advance through phases: Phase 1 tests safety in a small group, Phase 2 evaluates effectiveness and side effects, Phase 3 confirms benefit in a larger population, and Phase 4 monitors long-term safety after FDA approval.
Note: This pipeline includes all of Ipsen's active interventional trials, not only those targeting rare diseases. We show the full pipeline because a company's broader research activity, therapeutic expertise, and development infrastructure directly shape its ability to advance rare disease programs. A strong overall pipeline often signals deeper clinical operations, faster enrollment capabilities, and greater commitment to bringing new treatments to patients.
Ipsen Clinical Trials (19)
Active and recruiting clinical trials sponsored by Ipsen, sourced live from ClinicalTrials.gov. Each trial card shows the study phase, current recruitment status, conditions under investigation, study locations, eligibility criteria, and a direct link to the full ClinicalTrials.gov record. You can also download a one-page PDF summary to share with your doctor.
Note: Recruitment statuses on ClinicalTrials.gov may not immediately reflect recent FDA decisions, sponsor announcements, or enrollment changes. Always confirm a trial's current status directly with the study coordinator.
Ipsen FDA-Approved Drugs (5)
Medications developed or marketed by Ipsen that have received U.S. Food and Drug Administration approval. Drug data is sourced from the openFDA database and includes brand names, generic names, approval dates, and matched rare disease indications. Where a drug treats a condition covered by Trial Friend, the disease name links directly to that disease page.
| Drug Name | Brand Name | Rare Diseases | Approval Date |
|---|---|---|---|
| ODEVIXIBAT Ileal Bile Acid Transporter Inhibitor [EPC] | Bylvay oral | Jul 20, 2021 | |
| MECASERMIN | Increlex subcutaneous | Aug 30, 2005 | |
| ELAFIBRANOR Peroxisome Proliferator-activated Receptor Agonist [EPC] | IQIRVO oral | Jun 10, 2024 | |
| IRINOTECAN HYDROCHLORIDE | Onivyde intravenous | Oct 22, 2015 | |
| LANREOTIDE ACETATE | SOMATULINE DEPOT subcutaneous | Aug 30, 2007 |
Ipsen Trial Locations
Ipsen clinical trials are running at 685 sites in 37 countries. Click any country to drill down by state, city, and individual research facility. Proximity to a trial site is one of the most important factors in deciding whether to participate.
Rare Disease Focus Areas (17)
Diseases targeted by Ipsen's clinical trial and drug development programs
Acromegaly is a rare hormonal disorder caused by excessive growth hormone production, typically from a pituitary adenoma, resulting in abnormal growth of hands, feet, and facial features. It also caus...
Alagille syndrome is a rare autosomal dominant disorder affecting the liver, heart, skeleton, face, and eyes. The condition results from mutations in genes regulating the Notch signaling pathway, lead...
Duchenne muscular dystrophy is an X-linked genetic disorder causing progressive muscle weakness and degeneration, beginning in early childhood. The defective dystrophin protein normally protects muscl...
Fibrodysplasia Ossificans Progressiva (FOP) is an extremely rare genetic disorder characterized by progressive heterotopic ossification, where soft tissues (muscles, tendons, ligaments) gradually tran...
Friedreich ataxia is an autosomal recessive neurodegenerative disease causing progressive damage to the nervous system, resulting in loss of coordination (ataxia), weakness, and heart problems. The co...
Hemophilia A is an X-linked bleeding disorder caused by deficiency or dysfunction of clotting factor VIII. Severity depends on factor levels, ranging from mild to severe hemorrhage. Modern factor repl...
Patient Resources
Organizations and resources related to Ipsen's rare disease focus areas
Frequently Asked Questions About Ipsen
Common questions about Ipsen's rare disease programs, clinical trials, and treatments.